Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
4Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Dr. Verdine is one of Wave's founders and has served as a director since July 2013, previously serving as President, CEO and CSO. He is the Erving Professor of Chemistry, Emeritus at Harvard University and has co-founded numerous biopharmaceutical companies.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Amylyx Pharmaceuticals, Inc.

2015-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Amylyx Pharmaceuticals, Inc.

Open Amylyx Pharmaceuticals, Inc. profile →

Director at Amylyx Pharmaceuticals, Inc.

2015-01-01 → End not stated

current · source reported

Observed: 2026-09-16

Amylyx Pharmaceuti…Amylyx Pharmaceuticals, Inc.George Mclean Miln…

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingAMLX DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open sourceSource 2 · Sec FilingNUVB DEF 14A executive officersSupports Executive company, Executive title.Open sourceSource 3 · Sec FilingOMER 10-K executive officersSupports Executive company, Executive title.Open sourceSource 4 · Sec FilingBIIB 10-K executive officersSupports Executive company, Executive title.Open sourceSource 5 · Sec FilingWVE DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:george-mclean-milne-jr-ph-d
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

AI expertise · Source reportedAI expertise reported in filings1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

AI governance relevance · Source reportedAI governance relevance reported from role and filings1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board independence · Source reportedIndependent director1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of Amylyx Pharmaceuticals, Inc.Supported by 3 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Compensation, Nominating/Governance, Science/Innovation1 source
Verification
Source reported
Confidence
88%
Last reviewed
Apr 24, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive company · CorroboratedExecutive at Biogen Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 29, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive company · Source reportedExecutive at Nuvation Bio Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive company · Source reportedExecutive at OMEROS CORP1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive company · Source reportedExecutive at Wave Life Sciences Ltd.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive function · Source reportedPeople Talent (CHRO)1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · Source reportedExecutive title: Chief Scientific Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · CorroboratedExecutive title: Executive Vice President and Chief Human Resources OfficerSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 29, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · Source reportedExecutive title: Vice President, Science and Chief Scientific Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Other Company Role · Source reportedGregory L. Verdine, Ph.D. is also linked to LifeMine Therapeutics Inc. as President and Chief Executive Officer.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Technology background · CorroboratedTechnology background: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

View all sources9 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 24, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Director since · Board independence

  3. https://www.sec.gov/Archives/edgar/data/1658551/000119312526171800/amlx-20260422.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: Executive company · Executive title

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: Executive company · Executive title

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Apr 29, 2026

    Supports: Executive company · Executive title

  7. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  8. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: AI expertise · AI governance relevance · Executive company · Executive function · Executive title

  9. https://www.sec.gov/Archives/edgar/data/1658551/000119312526171800/amlx-20260422.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership